Pharmacokinetic Study of β-Methyldigoxin by Enzyme Immunoassay Using a Novel Specific Antiserum in Rats
We previously showed that enzyme immunoassay (EIA) of β-methyldigoxin (MDx3) using anti-MDx3 3′-hemisuccinate–bovine serum albumin antiserum (Antiserum-I) was superior to that using commercial anti-digoxin antiserum (Antiserum-II) in terms of specificity and that pretreatment of human serum with phe...
Saved in:
| Published in: | Biological & pharmaceutical bulletin Vol. 26; no. 2; pp. 247 - 251 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Tokyo
The Pharmaceutical Society of Japan
01-02-2003
Maruzen |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | We previously showed that enzyme immunoassay (EIA) of β-methyldigoxin (MDx3) using anti-MDx3 3′-hemisuccinate–bovine serum albumin antiserum (Antiserum-I) was superior to that using commercial anti-digoxin antiserum (Antiserum-II) in terms of specificity and that pretreatment of human serum with phenyl boric acid (PBA) column was effective. In the present study, we examined the precision of EIA using Antiserum-I and the recovery of MDx3 after PBA column treatment in rat serum, and also investigated pharmacokinetic changes of MDx3 in rats. The intra- and inter-assay variations and recovery tests using Antiserum-I were good. The PBA column was effective in selectively separating MDx3 from rat serum containing MDx3 and its metabolites. The recovery tests using Antiserum-I with PBA column showed about 110% and the interference of metabolites of MDx3 was negligible. Serum concentration–time courses of MDx3 by EIA using Antiserum-I with PBA column and Antiserum-I were lower than that using Antiserum-II. The distribution volume at steady state and total body clearance values of MDx3 in these conditions were significantly higher than those using Antiserum-II. The usefulness of PBA column was ascertained, while effects of PBA column on these parameters were not significant. In addition, rapid absorption of MDx3 was observed by EIA using Antiserum-I with PBA column. These results suggest that EIA using Antiserum-I with PBA column for the pretreatment of serum samples should be a more useful and valuable system in therapeutic drug monitoring and pharmacokinetic studies of the unchanged type of MDx3 than Antiserum-II. |
|---|---|
| AbstractList | We previously showed that enzyme immunoassay (EIA) of beta-methyldigoxin (MDx3) using anti-MDx3 3'-hemisuccinate-bovine serum albumin antiserum (Antiserum-I) was superior to that using commercial anti-digoxin antiserum (Antiserum-II) in terms of specificity and that pretreatment of human serum with phenyl boric acid (PBA) column was effective. In the present study, we examined the precision of EIA using Antiserum-I and the recovery of MDx3 after PBA column treatment in rat serum, and also investigated pharmacokinetic changes of MDx3 in rats. The intra- and inter-assay variations and recovery tests using Antiserum-I were good. The PBA column was effective in selectively separating MDx3 from rat serum containing MDx3 and its metabolites. The recovery tests using Antiserum-I with PBA column showed about 110% and the interference of metabolites of MDx3 was negligible. Serum concentration-time courses of MDx3 by EIA using Antiserum-I with PBA column and Antiserum-I were lower than that using Antiserum-II. The distribution volume at steady state and total body clearance values of MDx3 in these conditions were significantly higher than those using Antiserum-II. The usefulness of PBA column was ascertained, while effects of PBA column on these parameters were not significant. In addition, rapid absorption of MDx3 was observed by EIA using Antiserum-I with PBA column. These results suggest that EIA using Antiserum-I with PBA column for the pretreatment of serum samples should be a more useful and valuable system in therapeutic drug monitoring and pharmacokinetic studies of the unchanged type of MDx3 than Antiserum-II. We previously showed that enzyme immunoassay (EIA) of β-methyldigoxin (MDx3) using anti-MDx3 3′-hemisuccinate–bovine serum albumin antiserum (Antiserum-I) was superior to that using commercial anti-digoxin antiserum (Antiserum-II) in terms of specificity and that pretreatment of human serum with phenyl boric acid (PBA) column was effective. In the present study, we examined the precision of EIA using Antiserum-I and the recovery of MDx3 after PBA column treatment in rat serum, and also investigated pharmacokinetic changes of MDx3 in rats. The intra- and inter-assay variations and recovery tests using Antiserum-I were good. The PBA column was effective in selectively separating MDx3 from rat serum containing MDx3 and its metabolites. The recovery tests using Antiserum-I with PBA column showed about 110% and the interference of metabolites of MDx3 was negligible. Serum concentration–time courses of MDx3 by EIA using Antiserum-I with PBA column and Antiserum-I were lower than that using Antiserum-II. The distribution volume at steady state and total body clearance values of MDx3 in these conditions were significantly higher than those using Antiserum-II. The usefulness of PBA column was ascertained, while effects of PBA column on these parameters were not significant. In addition, rapid absorption of MDx3 was observed by EIA using Antiserum-I with PBA column. These results suggest that EIA using Antiserum-I with PBA column for the pretreatment of serum samples should be a more useful and valuable system in therapeutic drug monitoring and pharmacokinetic studies of the unchanged type of MDx3 than Antiserum-II. |
| Author | Fujii, Youichi Higashi, Yasuhiko Watanabe, Naomi Sasaki, Toshiyuki |
| Author_xml | – sequence: 1 fullname: Higashi, Yasuhiko organization: Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University – sequence: 2 fullname: Watanabe, Naomi organization: Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University – sequence: 3 fullname: Sasaki, Toshiyuki organization: Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University – sequence: 4 fullname: Fujii, Youichi organization: Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14576540$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/12576688$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0U9vFCEYBnBiauy2evEDGC56MJkVmBlgTqZpWm1S_8TaM2HgZZc6A9thxnT8WH4QP5OYnWyPXuDAj4c3PCfoKMQACL2kZE1ZJd-1u3bN-JpV4gla0bISRc1ofYRWpKGy4LSWx-gkpTtCiCCsfIaOKasF51Ku0PbrVg-9NvGHDzB6g2_Gyc44Ovznd_EJxu3cWb-JDz7gdsYX4dfcA77q-ylEnZKe8W3yYYM1_hx_QodvdmC8yzFnYfQJhqnH-eY3Pabn6KnTXYIXy36Kbi8vvp9_LK6_fLg6P7suDGdiLFyT529kSw1lQmqiGbOyNNBqR2VTtraEFrhtLFS8rqlkXHJDRWPAMgfWlafozT53N8T7CdKoep8MdJ0OEKekREkI50z-F1IhacMZz_DtHpohpjSAU7vB93qYFSXqXwEqF6AYV7mAjF8tqVPbg32ky49n8HoBOhnduUEH49Ojq7KrK5Ld-727S6PewAHoIbfUweHNZanE4cTkRhWE8i-5kqhw |
| CitedBy_id | crossref_primary_10_1007_s00216_010_4405_1 crossref_primary_10_1016_j_lfs_2005_03_003 |
| Cites_doi | 10.1093/clinchem/32.1.5 10.1093/clinchem/31.10.1625 10.1093/ajcp/82.2.210 10.1007/BF01062109 10.1093/clinchem/40.10.1898 10.1248/bpb.25.1251 10.1093/clinchem/40.1.172 10.1007/BF01177965 10.1002/jps.2600660304 10.1038/clpt.1984.11 10.1248/bpb.17.467 10.2131/jts.26.141 10.1097/00007691-199812000-00014 10.1248/cpb.32.2301 10.1093/clinchem/31.2.298 10.1089/hyb.1990.9.619 10.1002/jps.2600660228 10.1248/bpb.23.906 |
| ContentType | Journal Article |
| Copyright | 2003 The Pharmaceutical Society of Japan 2003 INIST-CNRS |
| Copyright_xml | – notice: 2003 The Pharmaceutical Society of Japan – notice: 2003 INIST-CNRS |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 7X8 |
| DOI | 10.1248/bpb.26.247 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Engineering Research Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1347-5215 |
| EndPage | 251 |
| ExternalDocumentID | 10_1248_bpb_26_247 12576688 14576540 article_bpb_26_2_26_2_247_article_char_en |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GroupedDBID | --- .55 1CY 23N 2WC 53G 5GY 6J9 AAUGY ABTAH ACGFO ACIWK ACPRK ADBBV AENEX AFFNX AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP CS3 DIK DU5 E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH KQ8 MOJWN OK1 P2P RJT RZJ TKC TR2 VH1 X7M XSB ZXP ZY4 IQODW ABJNI CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 7X8 |
| ID | FETCH-LOGICAL-c627t-f934798b1c1278a0a22d83cebaf1893bd3ebe6d9de4655182686c179ced2fedf3 |
| ISSN | 0918-6158 |
| IngestDate | Fri Aug 16 22:57:18 EDT 2024 Fri Aug 16 08:39:20 EDT 2024 Fri Aug 23 01:08:34 EDT 2024 Sat Sep 28 08:40:26 EDT 2024 Sun Oct 22 16:08:01 EDT 2023 Thu Aug 17 20:29:19 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | anti-β-methyldigoxin 3'-hemisuccinate-bovine serum albumin antiserum pharmacokinetic study enzyme immunoassay commercial anti-digoxin antiserum β-methyldigoxin phenyl boric acid column |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c627t-f934798b1c1278a0a22d83cebaf1893bd3ebe6d9de4655182686c179ced2fedf3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/bpb/26/2/26_2_247/_article/-char/en |
| PMID | 12576688 |
| PQID | 17819626 |
| PQPubID | 23462 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_73006628 proquest_miscellaneous_17819626 crossref_primary_10_1248_bpb_26_247 pubmed_primary_12576688 pascalfrancis_primary_14576540 jstage_primary_article_bpb_26_2_26_2_247_article_char_en |
| PublicationCentury | 2000 |
| PublicationDate | 2003-02-01 |
| PublicationDateYYYYMMDD | 2003-02-01 |
| PublicationDate_xml | – month: 02 year: 2003 text: 2003-02-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Tokyo |
| PublicationPlace_xml | – name: Tokyo – name: Japan |
| PublicationTitle | Biological & pharmaceutical bulletin |
| PublicationTitleAlternate | Biol Pharm Bull |
| PublicationYear | 2003 |
| Publisher | The Pharmaceutical Society of Japan Maruzen |
| Publisher_xml | – name: The Pharmaceutical Society of Japan – name: Maruzen |
| References | 12) Higashi Y., Watanabe N., Sasaki T., Fujii Y., Biol. Pharm. Bull., 25, 1251—1257 (2002). 16) Alan H. B. W., Terrie G. G., Clin. Chem., 31, 298—302 (1985). 9) Fujii Y., Ikeda Y., Yamazaki M., Clin. Chem., 40, 172—173 (1994). 2) Wahyono D., Piechaczyk M., Mourton C., Bastide J. M., Pau B., Hybridoma, 9, 619—629 (1990). 11) Ikeda Y., Fujii Y., Biol. Pharm. Bull., 23, 906—910 (2000). 1) Valdes R., Jr., Brown B. A., Graves S. W., Am. J. Clin. Pathol., 82, 210—213 (1984). 8) Thong B., Soldin S. J., Lingwood C. A., Clin. Chem., 31, 1625—1631 (1985). 20) Kobayashi Y., Suzuki M., Ohshiro N., Sunagawa T., Sasaki T., Tokuyama S., Yamamoto T., Yoshida T., J. Toxicol. Sci., 26, 141—150 (2001). 13) Haack E., Kaiser F., Spingler H., Naturwissenschaften, 44, 633—634 (1957). 21) Huang L., Wring S. A., Woolley J. L., Brouwer K. R., Serabjit-Singh C., Polli J. W., Drug Metab. Dispos., 29, 754—760 (2001). 7) Shimada K., Mizusawa S., Ohkubo T., Nambara T., Chem. Pharm. Bull., 32, 2301—2306 (1984). 5) Hinderling P. H., Garrett E. R., Wester R. C., J. Pharm. Sci., 66, 242—253 (1977). 17) Rameis H., Woodcock B., Bonelli J., Waginger H., Int. J. Clin. Pharmacol. Ther. Toxicol., 22, 145—151 (1984). 15) Dimson P. A., Analytiche. International (Current), 3, 4—5 (1984). 18) Soldin S. J., Clin. Chem., 32, 5—12 (1986). 3) Miller J. J., Straub R. W., Jr., Valdes R., Jr., Clin. Chem., 40, 1898—1903 (1994). 4) Gault M. H., Longerich L. L., Loo J. C. K., Ko P. T. H., Fine A., Vasdev S. C., Dawe M. A., Clin. Pharmacol. Ther., 35, 74—82 (1984). 6) Hinderling P. H., Garrett E. R., Wester R. C., J. Pharm. Sci., 66, 314—325 (1977). 10) Fujii Y., Ikeda Y., Fujii M., Yamazaki M., Biol. Pharm. Bull., 17, 467—471 (1994). 19) Datta P., Dasgupta A., Ther. Drug Monit., 20, 663—668 (1998). 14) Yamaoka N., Nakagawa T., Uno T., J. Pharmacokinet. Biopharm., 6, 547—558 (1978). Valdes R., Jr., Brown B. A., Graves S. W. (1) 1984; 82 12 Haack E., Kaiser F., Spingler H. (13) 1957; 44 Soldin S. J. (18) 1986; 32 Hinderling P. H., Garrett E. R., Wester R. C. (6) 1977; 66 Shimada K., Mizusawa S., Ohkubo T., Nambara T. (7) 1984; 32 Thong B., Soldin S. J., Lingwood C. A. (8) 1985; 31 Alan H. B. W., Terrie G. G. (16) 1985; 31 19 (2) 1990; 9 Miller J. J., Straub R. W., Jr., Valdes R., Jr. (3) 1994; 40 IKEDA Y (11) 2000; 23 Hinderling P. H., Garrett E. R., Wester R. C. (5) 1977; 66 Gault M. H., Longerich L. L., Loo J. C. K., Ko P. T. H., Fine A., Vasdev S. C., Dawe M. A. (4) 1984; 35 Dimson P. A. (15) 1984; 3 Rameis H., Woodcock B., Bonelli J., Waginger H. (17) 1984; 22 Yamaoka N., Nakagawa T., Uno T. (14) 1978; 6 FUJII Y (10) 1994; 17 Huang L., Wring S. A., Woolley J. L., Brouwer K. R., Serabjit-Singh C., Polli J. W. (21) 2001; 29 20 Fujii Y., Ikeda Y., Yamazaki M. (9) 1994; 40 |
| References_xml | – volume: 32 start-page: 5 year: 1986 ident: 18 publication-title: Clin. Chem. doi: 10.1093/clinchem/32.1.5 contributor: fullname: Soldin S. J. – volume: 31 start-page: 1625 year: 1985 ident: 8 publication-title: Clin. Chem. doi: 10.1093/clinchem/31.10.1625 contributor: fullname: Thong B., Soldin S. J., Lingwood C. A. – volume: 82 start-page: 210 issn: 0002-9173 year: 1984 ident: 1 publication-title: Am. J. Clin. Pathol. doi: 10.1093/ajcp/82.2.210 contributor: fullname: Valdes R., Jr., Brown B. A., Graves S. W. – volume: 6 start-page: 547 issn: 0090-466X year: 1978 ident: 14 publication-title: J. Pharmacokinet. Biopharm. doi: 10.1007/BF01062109 contributor: fullname: Yamaoka N., Nakagawa T., Uno T. – volume: 40 start-page: 1898 year: 1994 ident: 3 publication-title: Clin. Chem. doi: 10.1093/clinchem/40.10.1898 contributor: fullname: Miller J. J., Straub R. W., Jr., Valdes R., Jr. – volume: 29 start-page: 754 issn: 0090-9556 year: 2001 ident: 21 publication-title: Drug Metab. Dispos. contributor: fullname: Huang L., Wring S. A., Woolley J. L., Brouwer K. R., Serabjit-Singh C., Polli J. W. – ident: 12 doi: 10.1248/bpb.25.1251 – volume: 40 start-page: 172 year: 1994 ident: 9 publication-title: Clin. Chem. doi: 10.1093/clinchem/40.1.172 contributor: fullname: Fujii Y., Ikeda Y., Yamazaki M. – volume: 44 start-page: 633 issn: 0028-1042 year: 1957 ident: 13 publication-title: Naturwissenschaften doi: 10.1007/BF01177965 contributor: fullname: Haack E., Kaiser F., Spingler H. – volume: 66 start-page: 314 issn: 0022-3549 year: 1977 ident: 6 publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600660304 contributor: fullname: Hinderling P. H., Garrett E. R., Wester R. C. – volume: 35 start-page: 74 issn: 0009-9236 issue: 1 year: 1984 ident: 4 publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.1984.11 contributor: fullname: Gault M. H., Longerich L. L., Loo J. C. K., Ko P. T. H., Fine A., Vasdev S. C., Dawe M. A. – volume: 17 start-page: 467 issn: 0918-6158 issue: 4 year: 1994 ident: 10 publication-title: Biol. Pharm. Bull. doi: 10.1248/bpb.17.467 contributor: fullname: FUJII Y – volume: 3 start-page: 4 year: 1984 ident: 15 publication-title: Analytiche. International (Current) contributor: fullname: Dimson P. A. – ident: 20 doi: 10.2131/jts.26.141 – ident: 19 doi: 10.1097/00007691-199812000-00014 – volume: 32 start-page: 2301 issn: 0009-2363 issue: 6 year: 1984 ident: 7 publication-title: Chem. Pharm. Bull. doi: 10.1248/cpb.32.2301 contributor: fullname: Shimada K., Mizusawa S., Ohkubo T., Nambara T. – volume: 22 start-page: 145 year: 1984 ident: 17 publication-title: Int. J. Clin. Pharmacol. Ther. Toxicol. contributor: fullname: Rameis H., Woodcock B., Bonelli J., Waginger H. – volume: 31 start-page: 298 year: 1985 ident: 16 publication-title: Clin. Chem. doi: 10.1093/clinchem/31.2.298 contributor: fullname: Alan H. B. W., Terrie G. G. – volume: 9 start-page: 619 issn: 0272-457X issue: 6 year: 1990 ident: 2 publication-title: Hybridoma doi: 10.1089/hyb.1990.9.619 – volume: 66 start-page: 242 issn: 0022-3549 year: 1977 ident: 5 publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600660228 contributor: fullname: Hinderling P. H., Garrett E. R., Wester R. C. – volume: 23 start-page: 906 issn: 0918-6158 issue: 8 year: 2000 ident: 11 publication-title: Biol. Pharm. Bull. doi: 10.1248/bpb.23.906 contributor: fullname: IKEDA Y |
| SSID | ssj0007023 |
| Score | 1.7108333 |
| Snippet | We previously showed that enzyme immunoassay (EIA) of β-methyldigoxin (MDx3) using anti-MDx3 3′-hemisuccinate–bovine serum albumin antiserum (Antiserum-I) was... We previously showed that enzyme immunoassay (EIA) of beta-methyldigoxin (MDx3) using anti-MDx3 3'-hemisuccinate-bovine serum albumin antiserum (Antiserum-I)... We previously showed that enzyme immunoassay (EIA) of beta -methyldigoxin (MDx3) using anti-MDx3 3'-hemisuccinate-bovine serum albumin antiserum (Antiserum-I)... |
| SourceID | proquest crossref pubmed pascalfrancis jstage |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 247 |
| SubjectTerms | Animals anti-β-methyldigoxin 3′-hemisuccinate–bovine serum albumin antiserum Biological and medical sciences commercial anti-digoxin antiserum enzyme immunoassay Immune Sera - analysis Immunoenzyme Techniques - methods Male Medical sciences Medigoxin - administration & dosage Medigoxin - pharmacokinetics pharmacokinetic study phenyl boric acid column Rats Rats, Wistar β-methyldigoxin |
| Title | Pharmacokinetic Study of β-Methyldigoxin by Enzyme Immunoassay Using a Novel Specific Antiserum in Rats |
| URI | https://www.jstage.jst.go.jp/article/bpb/26/2/26_2_247/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/12576688 https://search.proquest.com/docview/17819626 https://search.proquest.com/docview/73006628 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biological and Pharmaceutical Bulletin, 2003, Vol.26(2), pp.247-251 |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELa6gQQSQtAxKD-GJdBeuozWCY7zWI1WmxgDsU7aW-TEDs26JhVpEOGv52wnTguagAdeoiqJ3arfl_PdOfcdQq85Z16ccOYIL4AABayfwz0xcIRLgc7SDxJdPnZ87p9dsndjb9zpNJoM7bn_ijScA6xV5ew_oG0nhRPwGTCHI6AOx7_C_VOtRT0H91GJsZ43qtGRXPG-80ECMtci_ZJ_TzPle46zH9VC9k9UnUgOnjSv-uY1At4_y7_Ja9OhPoGZRplu3FwuVI7kMzcSUHZDOLVWVJFpOdtIlUfrIt8m0a2aOGn7z4tyls7zNrMP7iqPpDH9-SK1OSBecNNje5rD2Kqc20uT8io1k-VlGs_SjVSG27z93OYkgSrgYrF182wK6msaknVba6Q662WbGN3a31YE4qkqh2gZHRJ6aIesy26ffQwnF6en4XR8Od1CtwhYLB2bn7y3S7o_0H0C7e-rdW5h7jftzBueze0rcO6VasO9JS_gj05Mm5Sb4xjtz0wfoPt1IIJHhkEPUUdmXbQzyvgqX1R4H-tXg_WeSxfdOWraAnbRfk2w6gBP29q94kAPsTLo1Q6a_8JErJmI8wQrJuJNJuKowoaJeI2JWDMRc6yZiBsmYstEDCMVEx-hi8l4enTs1K09nJgSf-UkgapgZtEwHhKf8QEnRDA3lhFPhuBBR8IF40JFIKTS91MxMKMxrB2xFCSRInF30XaWZ_IJwgEPZED4Ww6BiSc8l9PIY0BTiOtlEA9lD71qYAmXRsElVJEvgBcCeCGhIYDXQ8wgZu-pn2B7T33wfHtF1UWCyemhvQ2M22_xIJiHiKiHXjaghwCW2pHjmczLIhz64JBTQm--Q7WToJSwHnps2NLOrlIFlLGnf5z9GbrbPm3P0fbqaylfoK1ClHua5j8BiQnTLw |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetic+Study+of+beta+-Methyldigoxin+by+Enzyme+Immunoassay+Using+a+Novel+Specific+Antiserum+in+Rats&rft.jtitle=Biological+%26+pharmaceutical+bulletin&rft.au=Higashi%2C+Yasuhiko&rft.au=Watanabe%2C+Naomi&rft.au=Sasaki%2C+Toshiyuki&rft.au=Fujii%2C+Youichi&rft.date=2003-02-01&rft.issn=0918-6158&rft.volume=26&rft.issue=2&rft.spage=247&rft.epage=251&rft_id=info:doi/10.1248%2Fbpb.26.247&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon |